TY - JOUR
T1 - Modifying Effect of Statins on Fatal Outcomes in Chronic Kidney Disease Patients in the Systolic Blood Pressure Intervention Trial
T2 - A Post Hoc Analysis
AU - Rivera, Manuel
AU - Tamariz, Leonardo
AU - Suarez, Maritza
AU - Contreras, Gabriel
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Management of chronic kidney disease (CKD) patients includes efforts directed toward modifying traditional cardiovascular risk factors. Such efforts include optimal management of hypertension together with the initiation of statin therapy. >bold<>italic<Methods:>/italic<>/bold< In this observational study, we determine the modifying effect of statins on the relationship of systolic blood pressure (SBP) goal with mortality and other outcomes in patients with CKD participating in a clinical trial. At baseline, 2,646 CKD patients (estimated glomerular filtration rate < 60 mL/min/1.73 m>sup<2>/sup<) were randomized to an intensive SBP goal < 120 mm Hg or standard SBP goal <140 mm Hg. One thousand two hundred and seventy-three were not on statin, 1,354 were on a statin, and in 19 the use of statin was unknown. The 2 primary outcomes were all-cause mortality and cardiovascular disease (CVD) mortality. >bold<>italic<Results:>/italic<>/bold< The relationships of SBP goal with all-cause mortality (interaction >italic/italic< = 0.009) and cardiovascular (CV) mortality (interaction >italic/italic< = 0.021) were modified by the use of statin after adjusting for age, gender, race, CVD history, smoking, aspirin use, and blood pressure at baseline. In the statin group, targeting SBP to < 120 mm Hg compared to SBP < 140 mm Hg significantly reduced the risk of all-cause mortality (adjusted hazard ratio [aHR] 0.44 [0.28-0.71]; event rates 1.16 vs. 2.5 per 100 patient-years) and CV mortality (aHR 0.29 [0.12-0.74]; event rates 0.28 vs. 0.92 per 100 patient-years) after a median follow-up of 3.26 years. In the non-statin group, the risk of all-cause mortality (aHR 1.07 [0.69-1.66]; event rates 2.01 vs. 1.94 per 100 patient-years) and CV mortality (aHR 1.42 [0.56-3.59]; event rates 0.52 vs. 0.41 per 100 patient-years) were not significantly different in both SBP goal arms. >bold<>italic<Conclusion:>/italic<>/bold< The combination of statin therapy and intensive SBP management leads to improved survival in hypertensive patients with CKD.
AB - Management of chronic kidney disease (CKD) patients includes efforts directed toward modifying traditional cardiovascular risk factors. Such efforts include optimal management of hypertension together with the initiation of statin therapy. >bold<>italic<Methods:>/italic<>/bold< In this observational study, we determine the modifying effect of statins on the relationship of systolic blood pressure (SBP) goal with mortality and other outcomes in patients with CKD participating in a clinical trial. At baseline, 2,646 CKD patients (estimated glomerular filtration rate < 60 mL/min/1.73 m>sup<2>/sup<) were randomized to an intensive SBP goal < 120 mm Hg or standard SBP goal <140 mm Hg. One thousand two hundred and seventy-three were not on statin, 1,354 were on a statin, and in 19 the use of statin was unknown. The 2 primary outcomes were all-cause mortality and cardiovascular disease (CVD) mortality. >bold<>italic<Results:>/italic<>/bold< The relationships of SBP goal with all-cause mortality (interaction >italic/italic< = 0.009) and cardiovascular (CV) mortality (interaction >italic/italic< = 0.021) were modified by the use of statin after adjusting for age, gender, race, CVD history, smoking, aspirin use, and blood pressure at baseline. In the statin group, targeting SBP to < 120 mm Hg compared to SBP < 140 mm Hg significantly reduced the risk of all-cause mortality (adjusted hazard ratio [aHR] 0.44 [0.28-0.71]; event rates 1.16 vs. 2.5 per 100 patient-years) and CV mortality (aHR 0.29 [0.12-0.74]; event rates 0.28 vs. 0.92 per 100 patient-years) after a median follow-up of 3.26 years. In the non-statin group, the risk of all-cause mortality (aHR 1.07 [0.69-1.66]; event rates 2.01 vs. 1.94 per 100 patient-years) and CV mortality (aHR 1.42 [0.56-3.59]; event rates 0.52 vs. 0.41 per 100 patient-years) were not significantly different in both SBP goal arms. >bold<>italic<Conclusion:>/italic<>/bold< The combination of statin therapy and intensive SBP management leads to improved survival in hypertensive patients with CKD.
KW - Chronic kidney disease
KW - Hypertension
KW - Mortality
KW - Statin
UR - http://www.scopus.com/inward/record.url?scp=85063567636&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063567636&partnerID=8YFLogxK
U2 - 10.1159/000499188
DO - 10.1159/000499188
M3 - Article
C2 - 30917364
AN - SCOPUS:85063567636
VL - 49
SP - 297
EP - 306
JO - American Journal of Nephrology
JF - American Journal of Nephrology
SN - 0250-8095
IS - 4
ER -